Cargando…

582. Risk Factors for Progression to Hospitalization in Adolescents Presenting with Mild or Moderate COVID-19

BACKGROUND: Most adolescents (age 12-17 years) with COVID-19 have mild disease. However, certain comorbidities may be risk factors for disease progression, and hospitalization rates for this age group have increased. Adolescents and adults with mild to moderate COVID-19 are eligible for monoclonal a...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubois, Melanie, Campbell, Jeffrey, Lamb, Gabriella S, Nakamura, Mari M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644454/
http://dx.doi.org/10.1093/ofid/ofab466.780
_version_ 1784610089304326144
author Dubois, Melanie
Campbell, Jeffrey
Lamb, Gabriella S
Lamb, Gabriella S
Nakamura, Mari M
author_facet Dubois, Melanie
Campbell, Jeffrey
Lamb, Gabriella S
Lamb, Gabriella S
Nakamura, Mari M
author_sort Dubois, Melanie
collection PubMed
description BACKGROUND: Most adolescents (age 12-17 years) with COVID-19 have mild disease. However, certain comorbidities may be risk factors for disease progression, and hospitalization rates for this age group have increased. Adolescents and adults with mild to moderate COVID-19 are eligible for monoclonal antibody therapy. To identify subgroups likely to benefit from this intervention, we evaluated the relationship between comorbidities and need for hospitalization in US adolescents presenting with mild to moderate COVID-19. METHODS: We analyzed presence of comorbidities and need for hospitalization within 28 days of diagnosis for adolescents in the PIDTRAN registry, a multicenter retrospective cohort of US pediatric patients with COVID-19. Comorbidities assessed included obesity, chronic kidney disease (CKD), diabetes (DM), immunosuppressive disease or treatment (IS), sickle cell disease (SCD), congenital/acquired heart disease (CHD), neurologic disease/neurodevelopmental disorders (ND), medical-related technology dependence (MTD), and pulmonary disease requiring daily inhaled corticosteroids (PD). We used multivariable logistic regression to determine race/ethnicity-adjusted associations between comorbidities and hospitalization. RESULTS: 1574 patients met inclusion criteria, of whom 180 (11.4%) were hospitalized within 28 days of COVID-19 diagnosis. In a race/ethnicity-adjusted model, the following comorbidities were independently associated with increased odds of hospitalization: IS (OR 10.8 [95%CI 5.4 – 21.7]); CKD (OR 5.1 [95%CI 1.0 – 25.6]); DM (OR 4.2 [95%CI 1.7 – 10.6]); SCD (OR 3.4 [95%CI 1.1 – 10.6]). ND (OR 3.0 [95%CI 1.7 – 5.4]); and obesity (OR 2.0 [95%CI 1.1 – 3.9]). Notably, CHD, MTD, and PD were not independently associated with hospitalization. There was no effect modification of race/ethnicity on the association between obesity or DM and hospitalization. Table 1: Characteristics of adolescents in our cohort [Image: see text] Figure 1. Association between comorbidities and hospitalization. Model 1: comorbidities only. Model 2: comorbidities, adjusted for race/ethnicity. Abbreviations: CKD – chronic kidney disease; SCD – sickle cell disease; ICS – inhaled corticosteroids. [Image: see text] CONCLUSION: IS, CKD, DM, SCD, ND, and obesity were associated with increased odds of hospitalization in adolescents presenting with mild to moderate COVID-19. Adolescents with these comorbidities should be prioritized for consideration of treatment with monoclonal antibodies. DISCLOSURES: Gabriella S. Lamb, MD, MPH, Nothing to disclose
format Online
Article
Text
id pubmed-8644454
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86444542021-12-06 582. Risk Factors for Progression to Hospitalization in Adolescents Presenting with Mild or Moderate COVID-19 Dubois, Melanie Campbell, Jeffrey Lamb, Gabriella S Lamb, Gabriella S Nakamura, Mari M Open Forum Infect Dis Poster Abstracts BACKGROUND: Most adolescents (age 12-17 years) with COVID-19 have mild disease. However, certain comorbidities may be risk factors for disease progression, and hospitalization rates for this age group have increased. Adolescents and adults with mild to moderate COVID-19 are eligible for monoclonal antibody therapy. To identify subgroups likely to benefit from this intervention, we evaluated the relationship between comorbidities and need for hospitalization in US adolescents presenting with mild to moderate COVID-19. METHODS: We analyzed presence of comorbidities and need for hospitalization within 28 days of diagnosis for adolescents in the PIDTRAN registry, a multicenter retrospective cohort of US pediatric patients with COVID-19. Comorbidities assessed included obesity, chronic kidney disease (CKD), diabetes (DM), immunosuppressive disease or treatment (IS), sickle cell disease (SCD), congenital/acquired heart disease (CHD), neurologic disease/neurodevelopmental disorders (ND), medical-related technology dependence (MTD), and pulmonary disease requiring daily inhaled corticosteroids (PD). We used multivariable logistic regression to determine race/ethnicity-adjusted associations between comorbidities and hospitalization. RESULTS: 1574 patients met inclusion criteria, of whom 180 (11.4%) were hospitalized within 28 days of COVID-19 diagnosis. In a race/ethnicity-adjusted model, the following comorbidities were independently associated with increased odds of hospitalization: IS (OR 10.8 [95%CI 5.4 – 21.7]); CKD (OR 5.1 [95%CI 1.0 – 25.6]); DM (OR 4.2 [95%CI 1.7 – 10.6]); SCD (OR 3.4 [95%CI 1.1 – 10.6]). ND (OR 3.0 [95%CI 1.7 – 5.4]); and obesity (OR 2.0 [95%CI 1.1 – 3.9]). Notably, CHD, MTD, and PD were not independently associated with hospitalization. There was no effect modification of race/ethnicity on the association between obesity or DM and hospitalization. Table 1: Characteristics of adolescents in our cohort [Image: see text] Figure 1. Association between comorbidities and hospitalization. Model 1: comorbidities only. Model 2: comorbidities, adjusted for race/ethnicity. Abbreviations: CKD – chronic kidney disease; SCD – sickle cell disease; ICS – inhaled corticosteroids. [Image: see text] CONCLUSION: IS, CKD, DM, SCD, ND, and obesity were associated with increased odds of hospitalization in adolescents presenting with mild to moderate COVID-19. Adolescents with these comorbidities should be prioritized for consideration of treatment with monoclonal antibodies. DISCLOSURES: Gabriella S. Lamb, MD, MPH, Nothing to disclose Oxford University Press 2021-12-04 /pmc/articles/PMC8644454/ http://dx.doi.org/10.1093/ofid/ofab466.780 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Abstracts
Dubois, Melanie
Campbell, Jeffrey
Lamb, Gabriella S
Lamb, Gabriella S
Nakamura, Mari M
582. Risk Factors for Progression to Hospitalization in Adolescents Presenting with Mild or Moderate COVID-19
title 582. Risk Factors for Progression to Hospitalization in Adolescents Presenting with Mild or Moderate COVID-19
title_full 582. Risk Factors for Progression to Hospitalization in Adolescents Presenting with Mild or Moderate COVID-19
title_fullStr 582. Risk Factors for Progression to Hospitalization in Adolescents Presenting with Mild or Moderate COVID-19
title_full_unstemmed 582. Risk Factors for Progression to Hospitalization in Adolescents Presenting with Mild or Moderate COVID-19
title_short 582. Risk Factors for Progression to Hospitalization in Adolescents Presenting with Mild or Moderate COVID-19
title_sort 582. risk factors for progression to hospitalization in adolescents presenting with mild or moderate covid-19
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644454/
http://dx.doi.org/10.1093/ofid/ofab466.780
work_keys_str_mv AT duboismelanie 582riskfactorsforprogressiontohospitalizationinadolescentspresentingwithmildormoderatecovid19
AT campbelljeffrey 582riskfactorsforprogressiontohospitalizationinadolescentspresentingwithmildormoderatecovid19
AT lambgabriellas 582riskfactorsforprogressiontohospitalizationinadolescentspresentingwithmildormoderatecovid19
AT lambgabriellas 582riskfactorsforprogressiontohospitalizationinadolescentspresentingwithmildormoderatecovid19
AT nakamuramarim 582riskfactorsforprogressiontohospitalizationinadolescentspresentingwithmildormoderatecovid19